Drugs / CinnaPoietin®
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03408639 | Jun 2016 → Jul 2017 | aregenerative anemia | Cinnagen | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CinnaPoietin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03408639 ↗ |
| Known as | epoetin beta | “This phase III study aimed to compare the efficacy and safety of CinnaPoietin® (epoetin beta, CinnaGen) with Eprex® (epoetin alfa, Janssen Cilag) in the treatment of anemia in...” PMID 30253403 ↗ Sep 2018 |